Fujirebio is a Japanese multinational biotechnology company, founded and headquartered in

Tokyo Tokyo (; ja, 東京, , ), officially the Tokyo Metropolis ( ja, 東京都, label=none, ), is the capital and largest city of Japan. Formerly known as Edo, its metropolitan area () is the most populous in the world, with an estimated 37.468 ...

Japan Japan ( ja, 日本, or , and formally , ''Nihonkoku'') is an island country in East Asia. It is situated in the northwest Pacific Ocean, and is bordered on the west by the Sea of Japan, while extending from the Sea of Okhotsk in the north ...

, and present locally with offices in

Asia Asia (, ) is one of the world's most notable geographical regions, which is either considered a continent in its own right or a subcontinent of Eurasia, which shares the continental landmass of Afro-Eurasia with Africa. Asia covers an area ...

Europe Europe is a large peninsula conventionally considered a continent in its own right because of its great physical size and the weight of its history and traditions. Europe is also considered a Continent#Subcontinents, subcontinent of Eurasia ...

and the

United States The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territorie ...

and through a large international distribution network. The company has manufacturing facilities in Japan, Europe and the United States. Fujirebio specializes in innovation, development, manufacturing, and marketing of

in vitro diagnostics A medical test is a medical procedure performed to detect, diagnose, or monitor diseases, disease processes, susceptibility, or to determine a course of treatment. Medical tests such as, physical and visual exams, diagnostic imaging, genetic te ...

(IVD) testing

reagent In chemistry, a reagent ( ) or analytical reagent is a substance or compound added to a system to cause a chemical reaction, or test if one occurs. The terms ''reactant'' and ''reagent'' are often used interchangeably, but reactant specifies a ...

s, instruments, and software for clinical diagnostics and for research use. Fujirebio is today an H.U. Group company (listed on the

Tokyo Stock Exchange The , abbreviated as Tosho () or TSE/TYO, is a stock exchange located in Tokyo, Japan. It is the third largest stock exchange in the world by aggregate market capitalization of its listed companies, and the largest in Asia. It had 2,292 listed co ...

- TYO: 4544).

History

Fujirebio was founded in Tokyo, Japan in 1950 under the name Fujizoki Pharmaceutical, Co., Inc. In its early days the company developed and manufactured pharmaceutical products. The company's first IVD test was launched in 1966, a TPHA kit for syphilis testing. In 1983 the company changed name to Fujirebio Inc. Between 1998 and 2010 Fujirebio acquired several specialized IVD companies, notably Centocor Diagnostics (1998), CanAg Diagnostics (2006) and Innogenetics (2010). In 2005, Fujirebio Inc. was integrated together with the commercial laboratories SRL, Inc. ("Special Reference Laboratories", established in 1970) under the holding company Miraca Holdings Inc. (which was renamed to H.U. Group Holdings, Inc. in 2020). The current company structure, Fujirebio Holdings, Inc. was created in 2017 as a parent company of Fujirebio Inc., Fujirebio Diagnostics, Inc., Fujirebio Europe N.V. and other Fujirebio group companies. * 1950: Fujirebio (formerly Fujizoki Pharmaceutical, Co., Inc.) is founded in Tokyo, Japan. * 1966: Launch of HA Ag (TPHA), the world’s first

hemagglutination Hemagglutination, or haemagglutination, is a specific form of agglutination that involves red blood cells (RBCs). It has two common uses in the laboratory: blood typing and the quantification of virus dilutions in a haemagglutination assay. Blood ...

test for

syphilis Syphilis () is a sexually transmitted infection caused by the bacterium ''Treponema pallidum'' subspecies ''pallidum''. The signs and symptoms of syphilis vary depending in which of the four stages it presents (primary, secondary, latent, an ...

. * 1981: Established Fujirebio Taiwan Inc. * 1987: Established Fujirebio America, Inc. (merged to Fujirebio Diagnostics, Inc.) in the United States. * 1998: Acquisition of Centocor Diagnostics of Pennsylvania, Inc. (USA, currently Fujirebio Diagnostics, Inc.), pioneer in

oncology Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an ''oncologist''. The name's etymological origin is the Greek word ὄγκος (''ó ...

testing and developer of CA125II,

CA19-9 Carbohydrate antigen 19-9 (CA19-9), also known as sialyl-LewisA, is a tetrasaccharide which is usually attached to O- glycans on the surface of cells. It is known to play a role in cell-to-cell recognition processes. It is also a tumor marker used ...

and

CA15-3 CA 15-3, for Carcinoma Antigen 15-3, is a tumor marker for many types of cancer, most notably breast cancer. It is derived from MUC1. CA 15-3 and associated CA 27-29 are different epitopes on the same protein antigen product of the breast cancer ...

. * 2006: Acquisition of CanAg Diagnostics AB (Sweden, currently Fujirebio Diagnostics AB), leader in oncology biomarker development. * 2007: Launch of CL4800 in Japan to support blood

screening Screening may refer to: * Screening cultures, a type a medical test that is done to find an infection * Screening (economics), a strategy of combating adverse selection (includes sorting resumes to select employees) * Screening (environmental), a ...

for the

Japanese Red Cross Society The is the Japanese affiliate of the International Red Cross. The Imperial Family of Japan traditionally has supported the society, with the Empress as Honorary President and other imperial family members as vice presidents. Its headquarters ...

(~2019). * 2008: Acquisition of Advanced Life Science Institute, Inc. * 2008: Acquisition of American Biological Technologies, Inc. (merged to Fujirebio Diagnostics, Inc.). * 2010: Acquisition of

Innogenetics Innogenetics N.V. (now Fujirebio Europe N.V.) was an international in vitro diagnostics (IVD) company, with headquarters in Ghent, Belgium. Founded in 1985, the company developed and marketed IVD testing solutions as well as OEM raw materials. The ...

N.V. (Belgium, currently Fujirebio Europe N.V.), world leader in specialty

molecular A molecule is a group of two or more atoms held together by attractive forces known as chemical bonds; depending on context, the term may or may not include ions which satisfy this criterion. In quantum physics, organic chemistry, and bioche ...

and

immunoassay An immunoassay (IA) is a biochemical test that measures the presence or concentration of a macromolecule or a small molecule in a solution through the use of an antibody (usually) or an antigen (sometimes). The molecule detected by the immunoass ...

testing. * 2017: Established Fujirebio Holdings, Inc., as parent company of Fujirebio Inc., Fujirebio Diagnostics, Inc., Fujirebio Europe N.V. and other Fujirebio group companies. * 2019: Established Fujirebio Diagnostics Japan, Inc., focusing on OEM business in Japan. * 2020: Established Fujirebio China Co., Ltd.

References

Biotechnology companies of Japan Manufacturing companies based in Tokyo Chemical companies based in Tokyo Japanese brands Japanese companies established in 1950 Technology companies established in 1950 {{Japan-company-stub